ROS1 and metastatic malignant neoplasm in the lymph nodes: In terms of metastasis patterns, patients with ROS1 and RET fusions had a significantly higher incidence of distant lymph node metastases than patients with EGFR mutations (ROS1+ vs. EGFR+, 11.6% vs. 2.9%, p = 0.036; RET+ vs. EGFR+, 18.2% vs. 2.9%, p = 0.048).